Status:
COMPLETED
FACBC PET and PEM as a Staging Tool and Indicator of Therapeutic Response in Breast Cancer Patients
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborating Sponsors:
GE Healthcare
Conditions:
Breast Cancer
Eligibility:
FEMALE
21+ years
Phase:
EARLY_PHASE1
Brief Summary
This study has been designed to help us determine if FACBC PET or PEM can accurately evaluate how far the breast cancer has spread in the breast. Also, to help determine if FACBC PET or PEM can accura...
Eligibility Criteria
Inclusion
- Women presenting for evaluation at MSKCC with biopsy proven primary IDC or ILC
- No prior therapy for IDC or ILC
- Clinical need for local disease staging with breast MR (Group A only)
- Clinical need for neoadjuvant chemotherapy (Group B only)
- Patients must provide written informed consent
Exclusion
- Age \<21 years
- Men
- Pregnancy or lactation
- Patients who have already started treatment for the current malignancy
- Patients who cannot undergo PET scanning (i.e. because of weight limits)
- Patients who are known to have contraindication for MRI (e.g. metal implants)
- Patients may only participate in group #1 or group #2, but not both
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 29 2017
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01864083
Start Date
May 1 2013
End Date
August 29 2017
Last Update
August 31 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065